Redeye comments on Isofol’s announcement that the European Patent Office (EPO) has issued an “Intention to Grant” for a new product patent covering a stable lyophilized formulation of its lead candidate arfolitixorin. We view this as a meaningful milestone that likely extends patent protection for arfolitixorin into the mid-2040s, thereby strengthening the asset’s exclusivity profile and commercial potential.
